Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Rūta, Veinalde"'
Autor:
Rūta Veinalde, Gemma Pidelaserra-Martí, Coline Moulin, Lara M. Jeworowski, Linda Küther, Christian J. Buchholz, Dirk Jäger, Guy Ungerechts, Christine E. Engeland
Publikováno v:
Molecular Therapy: Oncolytics, Vol 24, Iss , Pp 43-58 (2022)
PD-1/PD-L1 checkpoint blockade has achieved unprecedented success in cancer immunotherapy. Nevertheless, many immune-excluded tumors are resistant to therapy. Combination with oncolytic virotherapy may overcome resistance by inducing acute inflammati
Externí odkaz:
https://doaj.org/article/b0640d5bf54b4f37a29eefe3f960eb3d
Autor:
Rūta Veinalde, Gemma Pidelaserra-Martí, Coline Moulin, Chin Leng Tan, Theresa E. Schäfer, Na Kang, Claudia R. Ball, Jonas Leichsenring, Albrecht Stenzinger, Lars Kaderali, Dirk Jäger, Guy Ungerechts, Christine E. Engeland
Publikováno v:
Frontiers in Immunology, Vol 13 (2023)
IntroductionPancreatic ductal adenocarcinoma (PDAC) is largely refractory to cancer immunotherapy with PD-1 immune checkpoint blockade (ICB). Oncolytic virotherapy has been shown to synergize with ICB. In this work, we investigated the combination of
Externí odkaz:
https://doaj.org/article/ba74acb47dae49da8309a7f9f1784388
Autor:
Rūta Veinalde, Christian Grossardt, Laura Hartmann, Marie-Claude Bourgeois-Daigneault, John C. Bell, Dirk Jäger, Christof von Kalle, Guy Ungerechts, Christine E. Engeland
Publikováno v:
OncoImmunology, Vol 6, Iss 4 (2017)
Combination of oncolytic virotherapy with immunomodulators is emerging as a promising therapeutic strategy for numerous tumor entities. In this study, we developed measles Schwarz vaccine strain vectors encoding immunomodulators to support different
Externí odkaz:
https://doaj.org/article/c94806dbf0f84599a829ae67877d0ae8
Autor:
Paul S. Backhaus, Rūta Veinalde, Laura Hartmann, Jessica E. Dunder, Lara M. Jeworowski, Jessica Albert, Birgit Hoyler, Tanja Poth, Dirk Jäger, Guy Ungerechts, Christine E. Engeland
Publikováno v:
Viruses, Vol 11, Iss 10, p 914 (2019)
Tumor-targeted immunomodulation using oncolytic viral vectors is currently being investigated as a promising strategy in cancer therapy. In a previous study, we showed that a measles virus Schwarz vaccine strain (MeVac) vector encoding an interleukin
Externí odkaz:
https://doaj.org/article/1118853372f84506bfe58b7fe879584d
Autor:
Christine E. Engeland, Linda Küther, Guy Ungerechts, Christian J. Buchholz, Dirk Jäger, Rūta Veinalde, Gemma Pidelaserra-Martí, Lara Maria Jeworowski, Coline Moulin
Publikováno v:
Molecular therapy, 24:43-58
Molecular Therapy: Oncolytics, Vol 24, Iss, Pp 43-58 (2022)
Molecular Therapy Oncolytics
Molecular Therapy: Oncolytics, Vol 24, Iss, Pp 43-58 (2022)
Molecular Therapy Oncolytics
PD-1/PD-L1 checkpoint blockade has achieved unprecedented success in cancer immunotherapy. Nevertheless, many immune-excluded tumors are resistant to therapy. Combination with oncolytic virotherapy may overcome resistance by inducing acute inflammati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e1f578f8f2b8a4e8d42ee9932982390
https://repository.publisso.de/resource/frl:6431729
https://repository.publisso.de/resource/frl:6431729
Autor:
Tobias Speck, Christof von Kalle, Guy Ungerechts, Christine E. Engeland, Rūta Veinalde, Johannes P W Heidbuechel, Claudia R. Ball, Dirk Jaeger
Publikováno v:
Clinical Cancer Research. 24:2128-2137
Purpose: Immunotherapy with bispecific T-cell engagers has achieved striking success against hematologic malignancies, but efficacy against solid tumors has been limited. We hypothesized that oncolytic measles viruses encoding bispecific T-cell engag
Autor:
Christoph Springfeld, Rūta Veinalde, Birgit Hoyler, Sascha Bossow, Roberto Cattaneo, Judith M Förster, Christine E. Engeland, Guy Ungerechts, Dirk Jäger, Andrew W. Hudacek
Publikováno v:
Journal of General Virology. 98:2248-2257
Viruses from the diverse family of Paramyxoviridae include important pathogens and are applied in gene therapy and for cancer treatment. The Tupaia paramyxovirus (TPMV), isolated from the kidney of a tree shrew, does not infect human cells and neutra
Autor:
Rūta, Veinalde
Publikováno v:
Methods in molecular biology (Clifton, N.J.). 2058
Oncolytic virotherapy is rapidly advancing into clinical practice as an appealing strategy for cancer therapy. Studies in the recent decades indicate that immunostimulatory properties of oncolytic viruses (OVs) are crucial for their therapeutic effic
Autor:
Christian Grossardt, Sascha Bossow, Ivan Shevchenko, Christof von Kalle, Dirk M. Nettelbeck, Diana Lutz, Wilko Weichert, Rūta Veinalde, Viktor Umansky, Guy Ungerechts, Dirk Jäger, Christine E. Engeland, Johanna K. Kaufmann
Publikováno v:
Molecular Therapy. 22(11):1949-1959
We hypothesized that the combination of oncolytic virotherapy with immune checkpoint modulators would reduce tumor burden by direct cell lysis and stimulate antitumor immunity. In this study, we have generated attenuated Measles virus (MV) vectors en
Autor:
Guna Proboka, Ainārs Baginskis, Simona Doniņa, Kristīne Azarjana, Anders Molven, Ingrīda Čēma, Rūta Veinalde, Aija Ozola, Dace Pjanova, Lars A. Akslen
Publikováno v:
Melanoma Research. 23:221-226
Hereditary cutaneous melanoma is associated with mutations in the high-risk CDKN2A gene in about 40% of melanoma-prone families. Mutations in the CDK4 gene are the cause in only a few pedigrees. In this study, we analyzed 20 Latvian familial melanoma